LIFECORE BIOMEDICAL, INC. \DE\

6. Property, plant and equipment, net

All property, plant and equipment is located in the United States. The following table presents the components of property, plant and equipment:

During the three months ended September 30, 2025, the Company completed its capacity expansion project which is expected to more than double its overall aseptic capacity. As a result of the completion of the capacity expansion project, depreciation expense is expected to increase by approximately $1,600 per annum.

On January 7, 2025, the Company entered into an agreement for the sale of certain excess equipment. The aggregate purchase price was$17,000. Lifecore received$7,000 cash and paid fees of$752 at closing. Lifecore also accepted a note for the remainder of the proceeds (see note 4) and recorded current and noncurrent payables of$800 and$200, respectively, for selling fees due to a third-party broker. The note and the payables were each cash-settled in June 2025. The sale resulted in a $21,239 reduction in idle construction in process. The Company recorded a loss on the sale of the equipment of$6,400, which is included with other losses for the fiscal year ended May 25, 2025, respectively, in loss on sale or disposal of assets, net of portion classified as cost of sales, within the statement of operations.

Depreciation and amortization expense for property, plant, and equipment for thethree months ended September 30, 2025 and August 25, 2024 was$1,981 and$1,993, respectively.